Stay updated on Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.4%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check32 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check39 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe page has updated clinical trial information, including new dates and identifiers, and extended the duration of study treatment from approximately 46 months to up to 66 months.SummaryDifference1%
Stay in the know with updates to Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Cervical Cancer Clinical Trial page.